Biogen (BIIB) Q3 2025 10-Q Quarterly Report
Filed: Oct 30, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Biogen (BIIB) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Biogen Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $2.535B for Q3 2025, up $68.9M (2.8%) YoY from $2.466B in Q3 2024
- • Operating margin approx. 21.7% in Q3 2025 ($557.3M income before tax on $2.535B revenue) vs 18.3% in Q3 2024 ($451.0M on $2.466B)
- • Best segment: Multiple Sclerosis product revenue grew to $1.0615B in Q3 2025 vs $1.0539B prior year; rare diseases segment revenue $533.3M vs $494.8M
- • Worst segment: Contract manufacturing, royalty and other revenue declined to $151.2M in Q3 2025 from $231.6M in Q3 2024
- • Cash and equivalents increased to $3.863B at Sept 30, 2025 from $2.375B at Dec 31, 2024; operating cash flow $1.693B for first nine months 2025 vs $2.115B prior-year period
- • Management notes continued profitability driven by multiple sclerosis and rare disease products, increased Alzheimer's collaboration revenue; ongoing restructuring and acquisitions incur expenses but expected to enable future growth
- • Near-term outlook cautious with acknowledgement of competitive, regulatory, and legal risks; no updated revenue guidance disclosed; focus on pipeline advancement and global commercial strategies
Risk Factors
- • New risk: Generic TECFIDERA competition started in North America, Brazil, Europe triggering revenue decline and ongoing patent litigation in Europe through 2028
- • Most updated risk: Impact of Inflation Reduction Act (IRA) Medicare Part D redesign expected to reduce 2025 revenue by $50-100M, mainly on SKYCLARYS and MS portfolio
- • Regulatory risk: OBBBA law signed July 2025 alters Medicaid funding and ACA subsidies; full impact on business remains uncertain pending further regulations
- • Operational risk: Supply chain disruptions risk from geopolitical tensions, tariffs, raw material shortages, plus reliance on international manufacturing for key products (TECFIDERA, LEQEMBI)
- • Financial risk: Liquidity strengthened to $4.0B cash and equivalents as of Sept 30, 2025; raised $1.75B via 2025 Senior Notes to redeem notes due Sept 2025, maintaining debt at $6.3B
Biogen Q3 2025 Quarterly FinancialsXBRL
Revenue
$2.5B
▲ +2.8% YoY▼ -4.2% QoQ
Net Income
$467M
▲ +20.1% YoY▼ -26.5% QoQ
Net Margin
18.4%
▲ +265bp YoY▼ -559bp QoQ
Source: XBRL data from Biogen Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Biogen
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.